Scientific Presentation | AAIC 2022
ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease – First Results of a Randomized, Placebo-Controlled, 26-Week, Phase 2 Proof-of-Concept Trial
Hans J. Moebius, Charles Bernick, Paul Winner, Joyce Maalouf, Kai-Bin Ooi, Samuel Dickson, Suzanne Hendrix, Kevin Church, and John M. Olichney
Download PDF
Watch Video
